coronary heart disease combined with hypertension
Conditions
Interventions
General management group:The study subjects all received routine secondary prevention treatment after coronary heart disease percutaneous coronary intervention (PCI), including blood pressure control
Intelligent blood pressure monitor group:The study subjects received routine secondary prevention treatment after coronary heart disease percutaneous coronary intervention (PCI) and were provided with
Intelligent management group:The study subjects received intelligent blood pressure monitors and an artificial intelligence management system for "patient-AI-doctor" collaborative blood pressure manag
Sponsors
The First Affiliated Hospital of USTC (Anhui Provincial Hospital)
Eligibility
Sex/Gender
All
Age
18 Years to 79 Years
Inclusion criteria
Inclusion criteria: 1) Age range of 18-79 years (inclusive), gender not limited; 2) Patients with clinical manifestations of coronary heart disease and successful PCI treatment; 3) Clinical diagnosis of primary hypertension, including patients with initial high blood pressure and those taking antihypertensive drugs. The diagnosis of hypertension is based on the Chinese Guidelines for the Prevention and Treatment of Hypertension 2018 Revision , with three consecutive office visits having blood pressures that meet the criteria: systolic blood pressure =140 mmHg and / or diastolic blood pressure =90 mmHg; patients with a history of hypertension, currently taking antihypertensive drugs, and even if their blood pressure is lower than 140/90 mmHg, should still be diagnosed as hypertension; 4) Selected patients or their legal guardians will be informed of the nature of the study, understand the provisions of the protocol, sign informed consent, and agree to receive study drugs and clinical follow-up.
Exclusion criteria
Exclusion criteria: 1.Acute heart failure; 2.NYHA functional classification IV; 3.Patient's condition is unstable or complications occur during percutaneous coronary intervention (PCI) during the current hospitalization; 4.Suspected or confirmed secondary hypertension; 5.Concurrent diseases that require the use of medications that may affect blood pressure, such as prostate disease, and may require adjustment of medication during the trial period; 6.Cardiovascular diseases such as stroke, heart failure, severe arrhythmia (high-degree atrioventricular block, ventricular tachycardia) occurring in the past 3 months; 7.Chronic renal insufficiency (creatinine >265umol/L); 8.Pregnancy or lactating women; 9.Hypertension (blood pressure >200/100mmHg); 10.Other diseases that are not suitable for participation in the trial, such as currently treated thyroid diseases, acute infectious diseases, mental and psychological disorders, and history of tumor diseases within 5 years; 11.Spouse has already participated in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| a composite of major adverse cardiac or cerebral events; | — |
Secondary
| Measure | Time frame |
|---|---|
| Incidence of bleeding events during follow-up;Target rate of blood pressure control in patients; | — |
Countries
China
Contacts
Public ContactLikun Ma
The First Affiliated Hospital of USTC (Anhui Provincial Hospital)
Outcome results
None listed